Status of current trials and potential future trials with sparsentan
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Expert opinion on emerging drugs - 28(2023), 3 vom: 01. Dez., Seite 145-147 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Trachtman, Howard [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
9242RO5URM |
|---|
| Anmerkungen: |
Date Completed 23.10.2023 Date Revised 23.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14728214.2023.2239151 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM359669026 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM359669026 | ||
| 003 | DE-627 | ||
| 005 | 20231226081352.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14728214.2023.2239151 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1198.xml |
| 035 | |a (DE-627)NLM359669026 | ||
| 035 | |a (NLM)37466432 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Trachtman, Howard |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Status of current trials and potential future trials with sparsentan |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.10.2023 | ||
| 500 | |a Date Revised 23.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Editorial | |
| 650 | 4 | |a IgA nephropathy | |
| 650 | 4 | |a Sparsentan | |
| 650 | 4 | |a clinical trials | |
| 650 | 4 | |a focal segmental glomerulosclerosis | |
| 650 | 4 | |a glomerular filtration rate | |
| 650 | 4 | |a proteinuria | |
| 650 | 7 | |a sparsentan |2 NLM | |
| 650 | 7 | |a 9242RO5URM |2 NLM | |
| 650 | 7 | |a Spiro Compounds |2 NLM | |
| 650 | 7 | |a Sulfonamides |2 NLM | |
| 700 | 1 | |a Komers, Radko |e verfasserin |4 aut | |
| 700 | 1 | |a Inrig, Jula |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert opinion on emerging drugs |d 2001 |g 28(2023), 3 vom: 01. Dez., Seite 145-147 |w (DE-627)NLM143290835 |x 1744-7623 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2023 |g number:3 |g day:01 |g month:12 |g pages:145-147 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14728214.2023.2239151 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 28 |j 2023 |e 3 |b 01 |c 12 |h 145-147 | ||